How were iBio's earnings last quarter?

iBio, Inc. (NYSEAMERICAN:IBIO) released its quarterly earnings data on Monday, May, 13th. The company reported ($0.71) EPS for the quarter.

How do I buy shares of iBio?

Shares of IBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

What other stocks do shareholders of iBio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that iBio investors own include Inovio Pharmaceuticals (INO) , Vaxart (VXRT) , Sorrento Therapeutics (SRNE) , VBI Vaccines (VBIV) , Heat Biologics (HTBX) , Novavax (NVAX) and Dynavax Technologies (DVAX) .

NYSEAMERICAN:IBIO

iBio (IBIO) Stock Price, News & Analysis

$2.25

+0.03 (+1.35%)

(As of 07/26/2024 ET)

Compare

Today's Range: $2.20
▼
$2.27
50-Day Range: N/A
52-Week Range: $1.02
▼
$15.99

Volume: 23,180 shs
Average Volume: 1.76 million shs
Market Capitalization: $7.83 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Earnings Short Interest

Get iBio alerts:

Ad Crypto 101 Media

Next opportunity for crypto millions

The Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has led to a massive bull run in the year after it happens. That means we're in the "golden window" right now…

Check out the new "Crypto Bull Run Millionaire Blueprint" now!

About iBio

iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.

IBIO Stock Price History

30 days | 90 days | 365 days | Advanced Chart

IBIO Stock News Headlines

July 23, 2024 | msn.com

Brookline Capital Initiates Coverage of iBio (IBIO) with Buy Recommendation

May 28, 2024 | msn.com

Chardan Capital Initiates Coverage of iBio (IBIO) with Buy Recommendation

July 27, 2024 | Stansberry Research (Ad)

Get out of cash before the Fed's next meeting

"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all $20,000 of his wife's 401k into shares of just ONE stock. Everyone on Wall Street said he was crazy. But a year later, that $20,000 in his wife's account was worth $120,000. Today, he says: "If you thought the dot-com mania was intense, what's about to happen in the coming weeks could be even crazier and could open up a new window of opportunity for 500%-plus gains."

March 27, 2024 | msn.com

US Futures Trend Higher Wednesday Pre-Bell as Investors Eye Impending Economic, Inflation Data Readings

March 27, 2024 | markets.businessinsider.com

IBio In Partnership With AstralBio; Shares Up In Pre-market

See More Headlines

Receive IBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for iBio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 5/13/2024
Today: 7/26/2024
Fiscal Year End: 6/30/2025

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSEAMERICAN
Sector: Medical
Industry: Biotechnology
Sub-Industry: Pharmaceutical Products
Current Symbol: NYSEAMERICAN:IBIO
CUSIP: N/A
CIK: N/A
Web: www.ibioinc.com
Phone: 302-355-0650
Fax: 302-356-1173
Employees: 100
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-65,010,000.00
Net Margins: N/A
Pretax Margin: -41,546.00%
Return on Equity: -150.59%
Return on Assets: -52.83%

Debt

Debt-to-Equity Ratio: 0.04
Current Ratio: 0.91
Quick Ratio: 0.91

Sales & Book Value

Annual Sales: $2.38 million
Price / Sales: 3.29
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $15.15 per share
Price / Book: 0.15

Miscellaneous

Outstanding Shares: 3,480,000
Free Float: 3,445,000
Market Cap: $7.83 million
Optionable: N/A
Beta: -3.77

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

Dr. Martin B. Brenner D.V.M. (Age 53)
Ph.D., CEO & Chief Scientific Officer
Comp: $577.31k
Mr. Felipe Duran (Age 44)
Chief Financial Officer
Comp: $1.07M
Stephen Kilmer
Investor Relations Officer
Mr. Marc Banjak J.D.
General Counsel
Mr. Robert B. Kay (Age 84)
Interim Secretary & Interim Treasurer
Comp: $92.69k

Key Competitors

View All Competitors

IBIO Stock Analysis - Frequently Asked Questions

How were iBio's earnings last quarter?: iBio, Inc. (NYSEAMERICAN:IBIO) released its quarterly earnings data on Monday, May, 13th. The company reported ($0.71) EPS for the quarter.
How do I buy shares of iBio?: Shares of IBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.
What other stocks do shareholders of iBio own?: Based on aggregate information from My MarketBeat watchlists, some other companies that iBio investors own include Inovio Pharmaceuticals (INO), Vaxart (VXRT), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Heat Biologics (HTBX), Novavax (NVAX) and Dynavax Technologies (DVAX).